Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is a direct-acting, reversible P2Y12 platelet inhibitor. It is a member of the cyclopentyltriazolopyrimidines (CPTP) class.
## Primary Indications
* In combination with aspirin, for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI).
* In combination with aspirin, for the prevention of thrombotic events in patients who have undergone percutaneous coronary intervention (PCI).
## Adult Dosing
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily.
* **For patients undergoing PCI:**
* Loading Dose: 180 mg orally once.
* Maintenance Dose: 90 mg orally twice daily for at least 12 months. Following this period, consider continuing 60 mg twice daily.
* Dosing duration depends on patient risk and clinical scenario, guided by local protocols and evidence-based guidelines.
## Pediatric Dosing
There is no established pediatric dosing for ticagrelor.
## Dose Adjustments
* **Hepatic Impairment:** No dose adjustment is necessary in patients with mild to moderate hepatic impairment. Use with caution in severe hepatic impairment as studies have not been conducted.
* **Renal Impairment:** No dose adjustment is necessary in patients with mild to moderate renal impairment. Use with caution in severe renal impairment.
* **Concomitant Medications:** See Key Drug Interactions.
## Contraindications
* Active bleeding (e.g., intracranial hemorrhage, gastrointestinal bleed).
* History of significant bleeding.
* Known hypersensitivity to ticagrelor or any component of the formulation.
## Adverse Effects
* **Most Common:** Dyspnea, bleeding (including fatal and severe bleeding), bradycardia.
* **Serious:** Life-threatening bleeding, ventricular pauses.
* **Other:** Hypotension, cough, rash, diarrhea, nausea.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Potent inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) can increase ticagrelor concentrations; potent inducers (e.g., rifampin, phenytoin, carbamazepine) can decrease ticagrelor concentrations.
* **Other Antiplatelet Agents/Anticoagulants:** Increased risk of bleeding. Use with caution and consider risk/benefit.
* **Gastroprotective Agents:** Proton pump inhibitors (PPIs) may interfere with ticagrelor's efficacy, particularly omeprazole and esomeprazole. Consider separate administration times or alternative gastroprotective agents if indicated.
* **Statins:** Ticagrelor can increase statin concentrations (especially simvastatin and lovastatin) due to CYP3A4 inhibition. Dose reduction of these statins may be necessary.
## Monitoring
* **Bleeding:** Monitor closely for signs and symptoms of bleeding.
* **Cardiac Rhythm:** Monitor for bradyarrhythmias, especially in patients with risk factors.
* **Renal and Hepatic Function:** Baseline and periodic monitoring may be considered, particularly in patients with significant impairment or those on interacting medications.
## Clinical Pearls
* Ticagrelor is a reversible P2Y12 inhibitor, unlike clopidogrel and prasugrel which are irreversible.
* Dyspnea is a common side effect and usually does not require discontinuation.
* Should be administered with aspirin; the dose of aspirin should generally not exceed 100 mg.
* Discontinuation of ticagrelor increases the risk of thrombotic events. If discontinuation is necessary for elective surgery, consider the risks and benefits.
***
*This information is for educational purposes and does not substitute for professional medical advice. Always consult the most current prescribing information and relevant guidelines before making any treatment decisions.*
